CHRS compared with KLRS: revenue, margins and what each company keeps, and the suppliers and customers both name

CHRSCoherus Oncology, Inc.

Mkt capRevenueRevenue

KLRSKalaris Therapeutics, Inc.

Mkt capRevenueRevenue

Compare

CHRSCoherus Oncology, Inc.

KLRSKalaris Therapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

CHRS

0 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±36.1%▼−12.76%×0.35

May 12 '26±12.4%▼−12.31%×0.99

Q1 FY26±34.7%▲+1.04%×0.03

Jan 13 '26±20.9%▲+3.03%×0.14

KLRS1 of 4 reports

Reportimpliedrealized× implied

Q2 FY26—▲+0.76%—

= impliedCHRS realized, solidKLRS realized, hatchedOne scale, both sides: full bar = 37%× = |realized| ÷ impliedSource: market data

CHRSCoherus Oncology, Inc.

0.77▲+2.39%· post 0.77

Mkt cap$119.0MRevenue$14MQ2 FY26Revenue$42MFY25

KLRSKalaris Therapeutics, Inc.

2.48▲+5.08%· post 2.48

ClosedNov 6 '26

Mkt cap$57.6MRevenue—Revenue—

Compare

ClosedNov 6 '26

CHRSCoherus Oncology, Inc.

KLRSKalaris Therapeutics, Inc.

0.77▲+2.39%post 0.77

Price

2.48▲+5.08%post 2.48

$119.0M

Mkt cap

$57.6M

Q2 FY26$14M

Revenue

—

FY25$42M

Revenue

—

CHRS0.77▲+2.39%vsKLRS2.48▲+5.08%ClosedNov 6 '26